Table 2.
Patient characteristics.
| DAPA HF | EMPEROR reduced | EMPEROR preserved | SOLOIST-WHF | DELIVER | |
|---|---|---|---|---|---|
| N | 4744 | 3730 | 5988 | 1222 | 6263 |
| Mean age | 66.3 | 67.35 | 71.85 | 69.50 | 71.65 |
| Female sex no. (%) | 1109 (23.4) | 893 (23.9) | 2676 (44.7) | 412 (33.7) | 2747 (43.9) |
| Race no. (%) | |||||
| Asian | 1116 (23.5) | 672 (18.0) | 824 (13.8) | 15 (1.2) | 1274 (20.3) |
| Black | 226 (4.8) | 257 (6.9) | 258 (4.3) | 50 (4.1) | 159 (2.5) |
| White | 3333 (70.3) | 2629 (70.5) | 4542 (75.9) | 1139 (93.2) | 4439 (70.9) |
| NYHA class — no. (%) | |||||
| II | 3203 (67.5) | 2800 (75.1) | 4883 (81.6) | – | 4713 (75.3) |
| III | 1498 (31.6) | 910 (24.4) | 1083 (18.1) | – | 1531 (24.5) |
| IV | 43 (0.9) | 20 (0.5) | 18 (0.3) | – | 18 (0.3) |
| Left ventricular ejection fraction | – | ||||
| Mean | 31.05 | 27.45 | 54.3 | 35 | 54.15 |
| ≤49 % | – | – | 1983 (33.1) | – | 2116 (33.8) |
| 50–59 % | – | – | 2058 (34.4) | – | 2256 (36.0) |
| ≥60 % | – | – | 1947 (32.5) | – | 1891 (30.2) |
| Median NT-proBNP (IQR) — pg/ml | 1437 | 1906.52 | 970.02 | 1778.71 | – |
| Atrial fibrillation | 1818 (38.3) | 1369 (36.7) | 3057 (51.1) | – | – |
| Type 2 diabetes mellitus no. (%) | 1983 (41.8) | 1856 (49.8) | 2938 (49.1) | – | 2806 (44.8) |
| Hypertension no. (%) | – | 2698 (72.3) | 5424 (90.6) | – | 5553 (88.7) |
| Mean eGFR | 65.75 | 62.00 | 60.6 | 49.85 | 61 |
| BMI | 28.15 | 27.90 | 29.83 | 30.75 | – |
| Medications | |||||
| Neprilysin inhibitor | 508 (10.7) | 727 (19.5) | – | 205 (16.8) | – |
| Beta-blocker | 4558 (96.1) | 3533 (94.7) | – | 1125 (92.1) | – |
| Mineralocorticoid receptor antagonist | 3370 (71.0) | 2661 (71.3) | – | 788 (64.5) | – |
| Device therapy | |||||
| Implantable cardioverter–defibrillator | 1242 (26.2) | 1171 (31.4) | – | – | – |
| Cardiac resynchronization therapy | 354 (7.5) | 442 (11.9) | – | – | – |
Abbreviations:
DAPA HF = Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; EMPEROR Reduced = Empagliflozin in Heart Failure with a Reduced Ejection Fraction; EMPEROR Preserved = Empagliflozin in Heart Failure with a Preserved Ejection Fraction; SOLOIST WHF = Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure; DELIVER = Dapagliflozin in Heart Failure with mildly reduced or preserved ejection fraction.